伊贝沙坦降低2型糖尿病肾病患者血清单核细胞趋化蛋白-1水平-东南大学学报医学版

伊贝沙坦降低2型糖尿病肾病患者血清单核细胞趋化蛋白-1水平

单位：1.东南大学附属中大医院,内分泌科,江苏,南京,210009； 2.江苏省人民医院,内分泌科,江苏,南京,210029； 3.东南大学,肾脏病研究所,江苏,南京,210009； 4.东南大学附属中大医院,临床免疫科,江苏,南京,210009； 5.东南大学,心血管病研究所,江苏,南京,210009

关键词：伊贝沙坦单核细胞趋化蛋白-1 糖基化终产物-肽糖尿病肾病 2型糖尿病

分类号：R587.2

出版年·卷·期（页码）：2007·26·第二期（83-86）

摘要：

目的:探讨伊贝沙坦对2 型糖尿病肾病患者血清糖基化终产物-肽(AGE-肽)和单核细胞趋化蛋白-1(MCP-1)水平的影响.方法:2型糖尿病伴微量白蛋白尿患者(尿白蛋白/肌酐30～300μg·mg-1)60例,随机分为实验组(口服瑞易宁加依贝沙坦)和对照组(仅口服瑞易宁),时间为6个月.流动注射分析法检测血清AGE-肽水平、ELISA法检测血清MCP-1水平.结果:实验组治疗后血清MCP-1水平较治疗前明显下降,且明显低于对照组;两组患者治疗后血清AGE-肽水平均较治疗前下降,实验组略低于对照组;实验组治疗后尿白蛋白/肌酐下降值与MCP-1下降值呈明显正相关.结论:伊贝沙坦通过降低2型糖尿病肾病患者血清MCP-1水平发挥肾保护效应.

Objective To investigate the effect of irbestartan on serum advanced glycosylation end products-peptide(AGE-P) and monocyte chemoatt ractant protein-1(MCP-1) in patients with nephropathy due to type 2 diabetes(DN).Methods 60 patients with type 2 diabetes with microalbuminuria(UMA 30-300 μg·mg-1) were conducted into two groups randomly.30 were treated with irbestartan plus glipizide and the others were treated with glipizide alone for six months.Serum AGE-P and MCP-1 were measured by flow injection assay and ELISA respectively before and after treatment.Results Serum MCP-1 in patients with irbestartan plus glipizide decreased significantly after treatment,showing significant difference as compared with that in patients with glipizide alone.Serum AGE-P in all patients was significantly decreased after treatment,but there was no significant difference between the two groups after treatment for three months.However,it was lower in patients with irbestartan plus glipizide after treatment for six months as compared with that in patients with glipizide alone.The reduction of proteinuria/creatinine correlated highly significant with the change in serum MCP-1.Conclusion Irbestartan reduces serum MCP-1 levels elevated in patients with nephropathy due to type 2 diabetes and suggests that irbestartan might play the role of reno-protection through suppression of the serum MCP-1.

参考文献：

[1] NISHOKA H, KANAUCHI M, DOHI K. Role of monocyte chemotactic peptide 1 in diabetic nephropathy. 2001(2). doi:10.1159/000045986
[2] LEEHEY D J, SINGH A K, ALAVI N. Role of angiotensin Ⅱ in DN. 2000. doi:10.1046/j.1523-1755.2000.07715.x
[3] 孙子林, 金晖, 李世云. 糖尿病肾病患者血清CC趋化因子升高并与AGE-肽相关. 东南大学学报(医学版)2005(6). doi:10.3969/j.issn.1671-6264.2005.06.008
[4] RUIZ-ORTEGA M, LORENZO O, EGIDO J. Angiotensin increase MCP-1 and actives NF-κB and AP-1 in cultured mesangial and mononuclear cells. 2000(6). doi:10.1046/j.1523-1755.2000.00089.x
[5] PARVING H H, LEHNERT H, BROCHNER-MORTENSEN J. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. 2001. doi:10.1056/NEJMoa011489
[6] 阎振成, 祝之明, 张建国. 糖尿病肾病患者尿MCP-1的变化及ACEI及Ang-Ⅱ受体拮抗剂对其影响. 第三军医大学学报2003(15)
[7] WADA T, FURUICHI K, SAKAI N. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. 2000(4). doi:10.1046/j.1523-1755.2000.00311.x
[8] 黄文辉, 倪安民. 单核细胞趋化蛋白-1、正常T 细胞活化表达和分泌调节蛋白与2 型糖尿病肾病患者肾小管间质损害的关系研究. 临床荟萃2004(7). doi:10.3969/j.issn.1004-583X.2004.07.002
[9] KATO S, LUYCKX V A, OTS M. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. 1999(3). doi:10.1046/j.1523-1755.1999.00643.x
[10] BANBA N, NAKAMURA T, MATSUMURA M. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. 2000(2). doi:10.1046/j.1523-1755.2000.00214.x

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录